INT32344

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.80
First Reported 1987
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 30
Total Number 31
Disease Relevance 15.28
Pain Relevance 10.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (LTF) extracellular region (LTF) cytoplasm (LTF)
Anatomy Link Frequency
neutrophils 8
pore 2
motor neurons 2
plasma 1
PGE1 1
LTF (Homo sapiens)
Pain Link Frequency Relevance Heat
Morphine 1648 100.00 Very High Very High Very High
lidocaine 8 98.76 Very High Very High Very High
Action potential 36 98.54 Very High Very High Very High
Inflammation 184 98.52 Very High Very High Very High
qutenza 22 98.18 Very High Very High Very High
spastic colon 75 97.20 Very High Very High Very High
cytokine 23 93.88 High High
hyperexcitability 27 88.80 High High
opioid receptor 336 79.84 Quite High
Inflammatory response 28 75.76 Quite High
Disease Link Frequency Relevance Heat
Disease 322 100.00 Very High Very High Very High
Lymphatic Filariasis 89 100.00 Very High Very High Very High
Obesity 53 100.00 Very High Very High Very High
Inflammatory Bowel Disease 354 99.92 Very High Very High Very High
Dengue 127 99.92 Very High Very High Very High
Infection 248 99.66 Very High Very High Very High
INFLAMMATION 189 98.40 Very High Very High Very High
Irritable Bowel Syndrome /

Irritable Bowel Syndrome Super

75 97.20 Very High Very High Very High
Pulmonary Alveolar Proteinosis 69 96.88 Very High Very High Very High
Diabetes Mellitus 30 96.28 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Lactoferrin (LF) is a protein secreted by the tissues of ectodermal origin.
Localization (secreted) of LF
1) Confidence 0.80 Published 2005 Journal Neurol. Neurochir. Pol. Section Abstract Doc Link 16355306 Disease Relevance 0.27 Pain Relevance 0.04
Lactoferrin (LF) is a protein secreted by the tissues of ectodermal origin.
Localization (secreted) of Lactoferrin
2) Confidence 0.80 Published 2005 Journal Neurol. Neurochir. Pol. Section Abstract Doc Link 16355306 Disease Relevance 0.27 Pain Relevance 0.04
Repetitive capsaicin challenge every 10 minutes led to tachyphylaxis of symptoms, total protein secretion, and lactoferrin secretion.
Localization (secretion) of lactoferrin associated with qutenza
3) Confidence 0.77 Published 1994 Journal J. Allergy Clin. Immunol. Section Abstract Doc Link 7798536 Disease Relevance 0.15 Pain Relevance 0.78
On the other hand, lactoferrin, a marker of glandular secretion, was increased (p < 0.005).
Localization (secretion) of lactoferrin
4) Confidence 0.77 Published 1994 Journal J. Allergy Clin. Immunol. Section Abstract Doc Link 7798536 Disease Relevance 0.16 Pain Relevance 0.78
Lactotransferrin (or lactoferrin), cathelicidin (or LL-37) and the defensins are all present in mucosal secretions, are produced at high levels by neutrophils, and have all been shown to have antiviral (especially anti-HIV) activity [32], [33], [34], [35], [36].
Localization (secretions) of lactoferrin in neutrophils associated with acquired immune deficiency syndrome or hiv infection
5) Confidence 0.66 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2886038 Disease Relevance 1.26 Pain Relevance 0
Lactotransferrin (or lactoferrin), cathelicidin (or LL-37) and the defensins are all present in mucosal secretions, are produced at high levels by neutrophils, and have all been shown to have antiviral (especially anti-HIV) activity [32], [33], [34], [35], [36].
Localization (secretions) of Lactotransferrin in neutrophils associated with acquired immune deficiency syndrome or hiv infection
6) Confidence 0.66 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2886038 Disease Relevance 1.27 Pain Relevance 0
At 120 minutes, lidocaine (100 mumol/L), which inhibits neutrophil activation, delayed release of lactoferrin (1.33 +/- 0.26 micrograms/mL) and markedly inhibited release of elastase (0.24 +/- 0.05 microgram/mL) but did not inhibit release of beta-TG antigen (5.66 micrograms/mL at 120 minutes).
Localization (release) of lactoferrin in neutrophil associated with lidocaine
7) Confidence 0.65 Published 1987 Journal Blood Section Abstract Doc Link 2947645 Disease Relevance 0 Pain Relevance 0.15
In this report, we explore mechanisms of the activation of neutrophils during simulated in vitro extracorporeal circulation and document the release of neutrophil lactoferrin and elastase during clinical cardiopulmonary bypass (CCB).
Localization (release) of lactoferrin in neutrophil
8) Confidence 0.65 Published 1987 Journal Blood Section Abstract Doc Link 2947645 Disease Relevance 0 Pain Relevance 0.09
PGE1 (0.3 mumol/L) inhibited significantly the release of beta-TG (0.31 microgram/mL) and elastase (0.52 +/- 0.11 microgram/mL) and attenuated the release of lactoferrin (1.57 +/- 0.45 micrograms/mL).
Localization (release) of lactoferrin in PGE1
9) Confidence 0.57 Published 1987 Journal Blood Section Abstract Doc Link 2947645 Disease Relevance 0 Pain Relevance 0.08
This may cause inefficient release of LF from the plasma proteins.
Localization (release) of LF in plasma
10) Confidence 0.54 Published 2010 Journal Analytical Chemistry Insights Section Body Doc Link PMC2865164 Disease Relevance 0 Pain Relevance 0
The key words inflammatory bowel diseases, Ulcerative colitis, CrohnÂ’s disease, fecal calprotectin, lactoferrin, serology and their equivalent Medical Subject Heading terms were used.


Localization (serology) of lactoferrin in bowel associated with inflammatory bowel disease, inflammation and disease
11) Confidence 0.16 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2827710 Disease Relevance 0.93 Pain Relevance 0.24
Fecal Lactoferrin
Localization (Fecal) of Lactoferrin
12) Confidence 0.16 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2827710 Disease Relevance 0.95 Pain Relevance 0.18
Several lines of evidence suggested that these supernumerary action potentials arose in motor axons and were responsible for the increased transmitter release underlying LTF.
Localization (release) of LTF associated with action potential
13) Confidence 0.14 Published 2008 Journal PLoS Genetics Section Body Doc Link PMC2581892 Disease Relevance 0 Pain Relevance 0.33
Individuals protected from acquiring infection (and subsequent LF disease)
Localization (disease) of LF associated with lymphatic filariasis, disease and infection
14) Confidence 0.14 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2879371 Disease Relevance 1.18 Pain Relevance 0
In addition to CRP and blood leukocytes, blinded fecal samples were measured for calprotectin (PhiCal Tesr, ELISA), lactoferrin (IBD-SCAN, ELISA), Hexagon-OBTI (immunochromatographic test for detection of human hemoglobin), and LEUKO-TEST (lactoferrin latex-agglutination test).
Localization (measured) of lactoferrin in leukocytes associated with inflammatory bowel disease
15) Confidence 0.14 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2827710 Disease Relevance 1.84 Pain Relevance 0.76
The observation that mGluR112b increases the rate of onset of LTF suggested that DmGluRA112b increases motor neuron excitability as well [16].
Localization (onset) of LTF in motor neuron
16) Confidence 0.13 Published 2008 Journal PLoS Genetics Section Body Doc Link PMC2581892 Disease Relevance 0 Pain Relevance 0.34
Lactotransferrin is an iron-binding protein that is released from activated neutrophils at sites of inflammation by the three types of granules [52] and has antimicrobial, as well as anti-inflammatory properties [53].
Localization (released) of Lactotransferrin in neutrophils associated with inflammation
17) Confidence 0.13 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2639705 Disease Relevance 0.50 Pain Relevance 0.21
We confirmed this prediction: larvae carrying the Foxo21/Foxo25 null combination and expressing PI3KDN in motor neurons exhibited a rate of onset of LTF, basal transmitter release, and failure frequency very similar to what was observed in the Foxo21/Foxo25 null mutant alone (Figure 3), or in larvae expressing PI3K-CAAX in motor neurons.
Localization (release) of LTF in motor neurons
18) Confidence 0.13 Published 2008 Journal PLoS Genetics Section Body Doc Link PMC2581892 Disease Relevance 0.09 Pain Relevance 0.14
Secretion efficiency was checked by Western blot analysis (see below) using an antibody against a secretion marker (i.e., lactoferrin).


Localization (secretion) of lactoferrin
19) Confidence 0.13 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2808358 Disease Relevance 0 Pain Relevance 0.19
PMN participate in the host defense via the secretion of particular antimicrobial peptides including lactoferrin, which is present in secondary granules and is released upon LPS stimulation [42], [47].
Localization (released) of lactoferrin
20) Confidence 0.13 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2808358 Disease Relevance 0.53 Pain Relevance 0.59

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox